IL-1 (cid:1) Receptor Antagonist Reduces Inflammation in Hemodialysis Patients

A. Hung,Charles D. Ellis,A. Shintani,Cindy Booker,T. Ikizler

Abstract:2 and the se-verity of joint erosions in rheumatoid ar-thritis. We designed a pilot double-blind randomized placebo controlled trial to evaluate the short-term efficacy of the administration of recombinant human IL-1ra on biomarkers of inflammation and nutrition in 22 MHD We hypothesized that the administration of 100 ABSTRACT Chronic inflammation is highly prevalent in maintenance hemodialysis (MHD) patients and associates with increased mortality. IL-1 (cid:3) , a pro-inflammatory cytokine, is elevated in MHD patients. A balance between IL-1 (cid:3) and its naturally occurring antagonist may determine the inflammatory response and its consequences in this population. We performed a pilot randomized placebo-controlled trial to evaluate the efficacy of the administration of recombinant human IL-1 receptor antagonist (IL-1ra) on biomarkers of inflammation and nutrition in MHD patients with three consecutive high sensitivity C-reactive protein (hsCRP) measurements (cid:1) 5 mg/L. We randomly assigned 22 patients to placebo or IL-1ra (1:1) for 4 weeks; 14 completed the trial. Patients in the IL-1ra arm had a 53% reduction in mean hsCRP compared with 1% in the placebo arm ( P (cid:2) 0.008), a 40% reduction in mean IL-6 levels compared with a 20% increase in the placebo arm ( P (cid:2) 0.03), and a 23% increase in mean prealbumin compared with 6% in the placebo arm ( P (cid:2) NS). In conclusion, the administration of IL-1ra in MHD patients can lower biomarkers of inflammation. Whether IL-1ra administration improves survival in this population requires additional long-term studies.